Schedule 13G ownership disclosure
LYELL IMMUNOPHARMA INC
Security class unavailable · CUSIP: 55083R104
Event date: 2021-12-31
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- Unavailable
- Percent of class
- 15.1000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001072613-22-000148
- Form type
- SC 13G
- Filer
- ARCH Venture Fund IX, L.P.
- CIK
- CIK 1666306
- Filed
- Feb 14, 2022
- Reporting period
- Dec 31, 2021
- Description
- Schedule 13G beneficial ownership